Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / MYO5A

MYO5A

Basics

Aliases:
This biomarker is also known as:
  • Myosin-12,
  • MYR12,
  • unconventional myosin-Va,
  • Myosin heavy chain 12,
  • myosin VA (heavy polypeptide 12, myoxin),
  • myoxin,
  • GS1,
  • myosin V,
  • MYO5,
  • myosin-12,
  • Dilute myosin heavy chain, non-muscle,
  • Myoxin,
  • myosin VA (heavy chain 12, myoxin),
  • MYH12,
  • myosin-Va,
  • dilute myosin heavy chain, non-muscle,
  • myosin, heavy polypeptide kinase,

View in BioMuta

Description…

The MYO5A gene is one of three myosin V heavy-chain genes, belonging to the myosin gene superfamily. The MYO5A protein functions as a processive actin-based motor that can move in large steps approximating the 36-nm pseudo-repeat of the actin filament. MYO5A is also involved in cytoplasmic vesicle transport and anchorage, spindle-pole alignment and mRNA translocation. Different isoforms, encoded by alternatively spliced transcript variants, have been reported.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: MYO5A

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data available.

Performance Comment

MYO5A was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.